Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ripretinib · 1 trial · 1 indication
PFS is defined as the time interval from randomization to the first occurrence of progressive disease based on assessment of the independent radiology review (IRR) or death due to any causes.
| Arm | Type | Description |
|---|---|---|
| Ripretinib | EXPERIMENTAL | 50mg/tablet,150 mg QD continuous administration, 6 weeks (42 days) for a cycle. |
| Sunitinib | ACTIVE_COMPARATOR | 12.5mg/capsule, 50 mg QD, in 6 weeks (42 days) with 4 weeks continuous dosing followed by 2 weeks break. |
| Name | Type | Description |
|---|---|---|
| Ripretinib | DRUG | Oral kinase inhibitor |
| Sunitinib | DRUG | second-line therapy in GIST patients who have progressed after imatinib treatment or are intolerant to imatinib |
Inclusion Criteria: * Male or female patients ≥18 years of age. * Histological diagnosis of advanced GIST and capability of providing tumor tissue sample (the interval between tumor tissue collection and signing of informed consent form should be less than 3 years). Otherwise, biopsy is required. *...
Ripretinib is an investigational small molecule being studied for the treatment of advanced Gastrointestinal Stromal Tumor (GIST) in patients who have previously been treated with imatinib. It is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
Ripretinib is being developed by Zai Lab Limited, a biopharmaceutical company traded on the NASDAQ under the ticker symbol ZLAB. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with advanced GIST.
Ripretinib is in Phase 2 clinical development. A completed Phase 2 trial assessed the drug in patients with advanced GIST after prior treatment with imatinib. The drug remains investigational and has not received regulatory approval.
Ripretinib has been evaluated in one completed clinical trial, identified as NCT04633122. This Phase 2 study, conducted in China, enrolled 108 patients with advanced GIST who had previously received imatinib. The trial was active-controlled, comparing Ripretinib to sunitinib.
Yes, Ripretinib is also known as DCC-2618. The clinical trial NCT04633122, which assessed the drug in advanced GIST, refers to it as DCC-2618. Both names refer to the same investigational small molecule being developed by Zai Lab Limited.